Brief: 4DMT Completes Enrollment Of Phase 2 Prism Clinical Trial For Intravitreal 4D-150 In Patients With Wet AMD And Reports Interim Safety And Tolerability Data

4D Molecular Therapeutics

17/07/2023 21:19

July 17 (Reuters) - 4D Molecular Therapeutics Inc
 FDMT.O :
    * 4DMT COMPLETES ENROLLMENT OF PHASE 2 PRISM CLINICAL TRIAL
FOR
INTRAVITREAL 4D-150 IN PATIENTS WITH WET AMD AND REPORTS INTERIM
SAFETY AND TOLERABILITY DATA
    * 4D MOLECULAR THERAPEUTICS INC - EXPECT TO PROVIDE UPDATE
REGARDING PHASE 3 PIVOTAL TRIAL PLANS IN Q1 2024 AFTER
DISCUSSION WITH FDA IN Q4 2023

Source text for Eikon:  ID:nGNXb3PBJD 
Further company coverage:  FDMT.O 

 (Reuters.Briefs@thomsonreuters.com)